Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5142042 | 1.00 | LMNA (0.56) | LMNAALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL11331822 | 1.00 | LMNA (0.56) | LMNAALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL27304612 | 1.00 | LMNA (0.56) | LMNAALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL27327697 | 1.00 | LMNA (0.56) | LMNAALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL3438481 | 1.00 | LMNA (0.56) | LMNAALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL4557001 | 1.00 | LMNA (0.56) | LMNAALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL648992 | 1.00 | LMNA (0.56) | LMNAALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL9208146 | 1.00 | LMNA (0.56) | LMNAALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL3632571 | 0.97 | ALDH1A1 (0.52) | LMNAALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL10422652 | 0.94 | LMNA (0.62) | LMNAALDH1A1TDP1TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160068638-A1 | ALIPHATIC POLYCARBONATE COMPOSITIONS AND METHODS | NOVOMER, INC. | 2016-03-10 | — | — | US | claimed |
| EP-2992031-A2 | ALIPHATIC POLYCARBONATE COMPOSITIONS AND METHODS | Novomer, Inc. (US) | 2016-03-09 | — | — | EP | claimed |
| WO-2014178972-A2 | ALIPHATIC POLYCARBONATE COMPOSITIONS AND METHODS | NOVOMER, INC. (US) | 2014-11-06 | — | — | WO | claimed |
| US-20250197341-A1 | METHOD FOR INHIBITING CRYSTALLISATION | BIOSYNTHIS (FR) | 2025-06-19 | — | — | US | disclosed |
| US-20250101326-A1 | PROCESS FOR MAKING ETHERS FROM ETHANOL | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4387582-A1 | METHOD FOR INHIBITING CRYSTALLISATION | Biosynthis (FR) | 2024-06-26 | — | — | EP | disclosed |
| CN-117940101-A | Method for inhibiting crystallization | 碧昂赛恩斯公司 | 2024-04-26 | — | — | CN | disclosed |
| WO-2023186171-A1 | CATIONIC LIPID, LIPOSOME, LIPID NANOPARTICLE, AND USE | 科镁信（上海）生物医药科技有限公司 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023186167-A1 | CATIONIC LIPID, LIPOSOME, LIPID NANOPARTICLE, AND USE | 科镁信（上海）生物医药科技有限公司 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023020979-A1 | METHOD FOR INHIBITING CRYSTALLISATION | BIOSYNTHIS (FR) | 2023-02-23 | — | — | WO | disclosed |
| EP-2992031-B1 | ALIPHATIC POLYCARBONATE COMPOSITIONS AND METHODS | NOVOMER INC (US) | 2022-10-05 | — | — | EP | disclosed |
| EP-2992031-A2 | ALIPHATIC POLYCARBONATE COMPOSITIONS AND METHODS | Novomer, Inc. (US) | 2016-03-09 | — | — | EP | disclosed |
| WO-2014178972-A2 | ALIPHATIC POLYCARBONATE COMPOSITIONS AND METHODS | NOVOMER, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| EP-0527378-B1 | Salicyl(thio)ethers derivatives, process and intermediates for their preparation | BASF AG (DE) | 1996-02-28 | — | — | EP | disclosed |
| EP-0527378-A1 | Salicyl(thio)ethers derivatives, process and intermediates for their preparation | BASF Aktiengesellschaft (DE) | 1993-02-17 | — | — | EP | disclosed |
| US-4631226-A | ACRYLATE AND OXIRANYL ACRYLATE COPOLYMERS, POLYAMINES FOR SHRINKAGE RESISTANCE IN WOOL, COTTON | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATION (AU) | 1986-12-23 | — | — | US | disclosed |
| EP-0006678-B1 | COMPOSITIONS FOR THE TREATMENT OF TEXTILE MATERIALS AND THE APPLICATION THEREOF | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1986-02-05 | — | — | EP | disclosed |
| US-4520143-A | CURABLE AQUEOUS EMULSION OF OXIRANE-CONTAINING ACRYLIC POLYMER AND POLYALKYLENE-AMINE; SHRINKAGE INHIBITION | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATION (AU) | 1985-05-28 | — | — | US | disclosed |
| US-4442241-A | WATER IN OIL EMULSION, CLAY, OIL SOLUBLE AMINE | EXXON RESEARCH AND ENGINEERING CO. (US) | 1984-04-10 | — | — | US | disclosed |
| EP-0006678-A1 | Compositions for the treatment of textile materials and the application thereof | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1980-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101326-A1 | PROCESS FOR MAKING ETHERS FROM ETHANOL | ADH1C, ADH1A, GK | LMNA 2096/4885ALDH1A1 335/4885TDP1 2259/4885 |
| US-20250197341-A1 | METHOD FOR INHIBITING CRYSTALLISATION | FASN, SCD5, NFKB2 | LMNA 149/4885ALDH1A1 3607/4885TDP1 3078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.